Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 expression. In metaplastic breast cancers (MpBC), there is limited expression of TROP2, and downregulating transcription factor ZEB1 upregulates...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ming, DiPeri, Timothy P., Raso, Maria Gabriela, Zheng, Xiaofeng, Rizvi, Yasmeen Qamar, Evans, Kurt W., Yang, Fei, Akcakanat, Argun, Roberto Estecio, Marco, Tripathy, Debu, Dumbrava, Ecaterina E., Damodaran, Senthil, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421911/
https://www.ncbi.nlm.nih.gov/pubmed/37567892
http://dx.doi.org/10.1038/s41523-023-00573-8

Ejemplares similares

Ejemplares similares